S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:XENE

Xenon Pharmaceuticals Stock Forecast, Price & News

$26.00
-3.12 (-10.71%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$25.87
$29.28
50-Day Range
$24.73
$31.99
52-Week Range
$13.98
$36.42
Volume
778,779 shs
Average Volume
571,599 shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.89
30 days | 90 days | 365 days | Advanced Chart
Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Xenon Pharmaceuticals logo

About Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Headlines

Xenon Pharmaceuticals (NASDAQ:XENE) Trading Down 5.2%
January 20, 2022 |  americanbankingnews.com
Xenon Pharmaceuticals (NASDAQ:XENE) Trading 4.2% Higher
January 14, 2022 |  americanbankingnews.com
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up to $30.50
January 10, 2022 |  americanbankingnews.com
Xenon Pharmaceuticals Inc. Common Shares (XENE)
December 22, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENE
Employees
129
Year Founded
N/A

Sales & Book Value

Annual Sales
$32.17 million
Book Value
$4.67 per share

Profitability

Net Income
$-28.84 million
Net Margins
-328.86%
Pretax Margin
-333.22%

Debt

Price-To-Earnings

Miscellaneous

Free Float
47,730,000
Market Cap
$1.34 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/23/2022
Next Earnings (Estimated)
3/07/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

289th out of 1,419 stocks

Pharmaceutical Preparations Industry

126th out of 685 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

Is Xenon Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Xenon Pharmaceuticals stock.
View analyst ratings for Xenon Pharmaceuticals
or view top-rated stocks.

How has Xenon Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XENE stock has increased by 104.6% and is now trading at $26.00.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Xenon Pharmaceuticals?

Xenon Pharmaceuticals saw a increase in short interest in the month of December. As of December 15th, there was short interest totaling 2,120,000 shares, an increase of 26.2% from the November 30th total of 1,680,000 shares. Based on an average daily trading volume, of 2,190,000 shares, the days-to-cover ratio is presently 1.0 days.
View Xenon Pharmaceuticals' Short Interest
.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Xenon Pharmaceuticals
.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.44) by $0.08. The biopharmaceutical company had revenue of $8.12 million for the quarter, compared to analyst estimates of $7.76 million. Xenon Pharmaceuticals had a negative net margin of 328.86% and a negative trailing twelve-month return on equity of 28.30%. During the same quarter last year, the company earned ($0.25) EPS.
View Xenon Pharmaceuticals' earnings history
.

What price target have analysts set for XENE?

5 Wall Street analysts have issued 1-year price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $40.00 to $48.00. On average, they expect Xenon Pharmaceuticals' stock price to reach $44.00 in the next year. This suggests a possible upside of 69.2% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:
  • Ian C. Mortimer, President, Chief Executive Officer & Director
  • Sherry Aulin, Chief Financial Officer
  • Sheila M. Grant, Senior VP-Research & Development Operations
  • Christopher Kenney, Chief Medical Officer
  • Robin Sherrington, Executive Vice President-Strategy & Innovation

What other stocks do shareholders of Xenon Pharmaceuticals own?

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.10%) and Cutler Group LP (0.00%). Company insiders that own Xenon Pharmaceuticals stock include Christopher John Kenney, Frank A Holler, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals
.

Which institutional investors are buying Xenon Pharmaceuticals stock?

XENE stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and Cutler Group LP. Company insiders that have bought Xenon Pharmaceuticals stock in the last two years include Christopher John Kenney, and Seggern Christopher Von.
View insider buying and selling activity for Xenon Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $26.00.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals has a market capitalization of $1.34 billion and generates $32.17 million in revenue each year. The biopharmaceutical company earns $-28.84 million in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals employs 129 workers across the globe.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

Where are Xenon Pharmaceuticals' headquarters?

Xenon Pharmaceuticals is headquartered at 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at [email protected], or via fax at 604-484-3450.


This page was last updated on 1/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.